Garry Taylor

Anthra Pharmaceuticals, Inc. is an American company.

Axellis, Inc. sells and distributes medical devices. Its products are used for oncology and cardiology. The company was founded in August 2007 and is headquartered in London, UK

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Part of Commerzbank AG, Commerzbank Finance Ltd. is a British company that provides securities brokerage services. The company is based in London, UK. Commerzbank Finance was founded in 1955.

Part of Pfizer Inc., Pfizer Group Ltd. is a British company that manufactures and sells pharmaceuticals, animal health products, and healthcare products. The company is based in Sandwich, UK.

Valtris Specialty Chemicals Ltd. develops, manufactures and sells additives for the polymer and coatings industries. It offers additives, antioxidants, metal stearates and lubricants, light stabilizers, blowing agents, pigments, waxes, non phthalate plasticizers, polymeric plasticizers, processing aids, flame retardants and viscosity modifiers. The company was founded in 1937 and is headquartered in Manchester, the United Kingdom.

BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom.

Stan Chem International Ltd. manufactures and supplies chemical products. It distributes chemical, raw materials and personal care products. The Company offers odour control, proprietary drugs, cosmetics, and skin and hair care products. The company was founded in 1977 and is headquartered in Reading, the United Kingdom..

Organon International, Inc. manufactures and markets pharmaceutical products. It develops therapeutics in the fields such as gynecology, fertility, osteoporosis, and anesthesia. The company was founded in 1923 and is located in Roseland, NJ.

GlaxoSmithKline Consumer Healthcare manufactures and supplies over the counter drugs. It focuses on oral healthcare, over the counter medicines and nutritional healthcare products. Its brands and products include oral care (Aquafresh) to dermatology (Zovirax), with all kinds of analgesics (Panadol), gastrointestinal remedies (Tums) and smoking-cessation products (Nicoderm). The company is headquartered in Brentford, UK

Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage.

Quantum Pharmaceutical Ltd. manufactures and supplies pharmaceutical products including oral solutions and suspensions, eye and nasal drops, and sterile injectables; ointments, creams, and pastes; and capsules, unit dose powders, suppositories, and reefers. It also offers borderline substances, short supply products, named patient items, white list appliances, branded generics, cover creams and dressings, colostomy and ostomy lines, and homeopathic products; and functional foods for special dietary needs. The firm serves pharmacists, chemists, hospitals, retailers and wholesalers, and dispensing doctors. The company was founded in 2004 and is headquartered in Burnopfield, the United Kingdom.

GT Biologics Ltd. manufactures and distributes pharmaceutical products. It develops and commercializes an oral-based probiotic product for the treatment of mild to moderate Crohn's disease and ulcerative colitis and a novel family of protein, peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases. The company was founded by Denise Kelly in 2008 and is headquartered in Leeds, the United Kingdom.

Akcros Holdings Ltd. provides additives for the processing and manufacturing of polymers, such as polyvinylchloride, polyurethane, polyolefins and is a specialty supplier of additives to the sealants, paint and coatings markets. The company delivers technical solutions from its manufacturing units in Europe, USA, India and China and has a proven track record of producing products. Akcros Holdings was founded in 1937 and is headquartered in Manchester, the United Kingdom.

Glaxosmithkline Consumer Healthcare UK No.1 Ltd. manufactures pharmaceutical products. The company was founded on March 13, 1963 and is headquartered in Camberley, the United Kingdom.

Martindale Pharmaceuticals Ltd. manufactures and distributes pharmaceutical products. The firm offers injectable products, pre-filled syringes, ophthalmic drops, ointments, oral solutions, and suppositories. The company was founded on September 22, 1972 and is headquartered in Romford, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Part of Triley Bidco Ltd., Colonis Pharma Ltd. is a British pharmaceutical company that manufactures and supplies pharmaceutical products. The company is based in Weybridge, UK. The company was founded in 2005 by Thomas Engelen. Colonis Pharma was acquired by Quantum Pharma Holdings Ltd., part of Triley Bidco Ltd. from November 02, 2017 on September 30, 2012.

BioMoti Ltd. provides cancer treatment and health care services. It offers a new class of immunotherapeutic drug-loaded particles that target and gain entry to the tumor vasculature and cancer cells. The company was founded by Joanne Martin and Davidson Ateh on June 6, 2009 and is headquartered in London, the United Kingdom.

HC 1228 Ltd. is a holding British company that operates through its subsidiaries to manufacture and distribute chemical and agrochemical products. The private company is based in Stratford-upon-Avon, UK. and has subsidiaries in United Kingdom. The company was founded in 2014.

Part of HC 1228 Ltd., HC1221 Ltd. operates as a holding British company with interest in production and distribution of chemicals and agrochemicals. The company is based in Stratford-upon-Avon, UK. Founded in 2013.

Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021.

Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue.

Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway.